CG Oncology, Inc. (CGON) Institutional Ownership

Ownership Summary

CG Oncology, Inc. (NASDAQ:CGON) appears in 190 institutional 13F filings for the quarter ending December 2025.

• Collectively, these holders controlled 102.9% of CG Oncology's outstanding shares in December 2025, up from 102.5% in September 2025.
• Their total shares held in CGON increased 6.34% from the prior quarter, while the number of investors in CG Oncology increased 36.69% year over year.
• Activity in CGON broke down as 110 buyers, 53 sellers, and 27 unchanged among 190 total holders.
• The aggregate institutional position in CG Oncology amounted to 78.95Mn shares as of December 2025, up by 4.71Mn shares quarter on quarter, and up 9.66Mn shares year over year.
• RTW INVESTMENTS, LP is the top holder of CG Oncology as of December 31, 2025, with 6.98Mn shares representing 9.1% of outstanding stock.
• The most significant purchases of CGON for the quarter ending December 2025 came from T. Rowe Price Investment Management, Inc. (6.26Mn), RTW INVESTMENTS, LP (4.97Mn), PRICE T ROWE ASSOCIATES INC /MD/ (3.65Mn), VANGUARD PORTFOLIO MANAGEMENT LLC (3.1Mn), VANGUARD CAPITAL MANAGEMENT LLC (3.03Mn).
• The largest sales of CGON for the quarter ending December 2025 came from Seven Fleet Capital Management LP (2.95Mn), Goldman Sachs Group Inc (1.49Mn), Pictet Asset Management Holding SA (951.52K), BRAIDWELL LP (885.79K), Opaleye Management Inc. (725.2K).
• Per Business Quant data, the top 10 holders of CG Oncology for the quarter ending December 2025 are RTW INVESTMENTS, LP (6.98Mn), T. Rowe Price Investment Management, Inc. (6.72Mn), Decheng Capital LLC (6.37Mn), WELLINGTON MANAGEMENT GROUP LLP (5.37Mn), BlackRock, Inc. (5.06Mn), FMR LLC (3.76Mn), TCG Crossover Management, LLC (3.67Mn), PRICE T ROWE ASSOCIATES INC /MD/ (3.65Mn), VANGUARD PORTFOLIO MANAGEMENT LLC (3.1Mn), VANGUARD CAPITAL MANAGEMENT LLC (3.03Mn).